B7-H3 expression in colorectal cancer: Associations with clinicopathological parameters and patient outcome

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ingebrigtsen, Vibeke A ^a,b   Boye, Kjetil ^a   Nesland, Jahn M ^a,b   Nesbakken, Arild ^b,c   Flatmark, Kjersti ^a   Fodstad, Øystein ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colorectal cancer; Nuclear B7 H3; Prognostic biomarker; Tissue microarray

Indexed keywords

PROTEIN B7 H3; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; STROMA CELL; TISSUE MICROARRAY; TREATMENT OUTCOME; COLORECTAL TUMOR; CYTOPLASM; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; B7 ANTIGENS; CELL MEMBRANE; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS;

EID: 84922690640     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-602     Document Type: Article

References (42)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in: GLOBOCAN 2008. Int J Cancer 2008, 2010(127):2893-2917.
2. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029.
3. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
4. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
5. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96:1420-1425.
6. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77.
7. Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL: Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005, 23:2318-2324.
8. Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, Carnaghi C, Doci R, Rosati R, Montorsi M, Roncalli M, Gennari L, Santoro A: Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007, 13:3831-3839.
9. Popat S, Houlston RS: A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005, 41:2060-2070.
10. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001, 2:269-274.
11. Collins M, Ling V, Carreno BM: The B7 family of immune-regulatory ligands. Genome Biol 2005, 6:223.
12. Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, Zhao JM, Zhang GB, Zhang XG: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 2006, 12:457-459.
13. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007, 104:19458-19463.
14. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008, 14:5150-5157.
15. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009, 9:463.
16. Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009, 101:1709-1716.
17. Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, Giuliano AE, Hoon DS: B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010, 252:1044-1051.
18. Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, Wang HT, Lu BF, Zhang XG: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 2010, 59:1163-1171.
19. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O: B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer 2012, 131:2528-2536.
20. Sun T-W, Gao Q, Qiu S-J, Zhou J, Wang X-Y, Yi Y, Shi J-Y, Xu Y-F, Shi Y-H, Song K, Xiao YS, Fan J: B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother 2012, 61:2171-2182.
21. Hofmeyer KA, Ray A, Zang X: The contrasting role of B7-H3. Proc Natl Acad Sci U S A 2008, 105:10277-10278.
22. Loos M, Hedderich DM, Friess H, Kleeff J: B7-h3 and its role in antitumor immunity. Clin Dev Immunol 2010, 2010:683875.
23. Chen YW, Tekle C, Fodstad O: The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 2008, 8:404-413.
24. Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, Liu Z, Ding Y, Wang B, Maelandsmo GM, Nesland JM, Fodstad O, Tan M: B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther 2011, 10(6):960-971. doi:10.1158/1535-7163.MCT-11-0072. Epub 2011 Apr 25.
25. Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, Fodstad O: B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 2011, 130(10):2282-2290. doi:10.1002/ijc.26238. Epub 2011 Aug 8.
26. Wang J, Chong KK, Nakamura Y, Nguyen L, Huang SK, Kuo C, Zhang W, Yu H, Morton DL, Hoon DS: B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma. J Invest Dermatol 2013, 133(8):2050-2058. doi:10.1038/jid.2013.114. Epub 2013 Mar 8.
27. Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong F, Zhang ZX, Zhang GB, Zhang XG, Zhao H: B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med 2013, 31:283-291.
28. Zhao X, Zhang GB, Gan WJ, Xiong F, Li Z, Zhao H, Zhu DM, Zhang B, Zhang XG, Li DC: Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett 2013, 5:805-812.
29. Merok MA, Ahlquist T, Royrvik EC, Tufteland KF, Hektoen M, Sjo OH, Mala T, Svindland A, Lothe RA, Nesbakken A: Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 2013, 24:1274-1282.
30. Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW: Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest 2007, 87:1206-1217.
31. Linderoth J, Ehinger M, Akerman M, Cavallin-Stahl E, Enblad G, Erlanson M, Jerkeman M: Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol 2007, 79:146-149.
32. Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED: Tissue microarrays: one size does not fit all. Diagn Pathol 2010, 5:48.
33. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007, 67:7893-7900.
34. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP: Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010, 23:1104-1112.
35. Quandt D, Fiedler E, Boettcher D, Marsch W, Seliger B: B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res 2011, 17:3100-3111.
36. Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, Aubry MC: Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013, 14:157-163.
37. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129.
38. Shen H, Zhou S, Wang J: The paradoxical role of Nrf2 in tumor biology. Crit Rev Eukaryot Gene Expr 2013, 23:37-47.
39. Luo L, Chapoval AI, Flies DB, Zhu G, Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, Liu Y, Chen L: B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 2004, 173:5445-5450.
40. Lupu CM, Eisenbach C, Kuefner MA, Schmidt J, Lupu AD, Stremmel W, Encke J: An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg 2006, 10:635-645.
41. Schneider T, Hoffmann H, Dienemann H, Schnabel PA, Enk AH, Ring S, Mahnke K: Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011, 6:1162-1168.
42. Chen C, Shen Y, Qu QX, Chen XQ, Zhang XG, Huang JA: Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res 2013, 319:96-102.